Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albiglutide in Heart Failure
NCT01357850Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2010
- Primary completion
- Sep 2012
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of albiglutide in heart failure (HF) (4 arms), sponsored by GSK. Primary endpoints: Change From Baseline in Myocardial Glucose Utilization as Assessed by [18F]Fluoro-2-deoxy-glucose Positron Emission Tomography (FDG-PET) Imaging at 13 weeks, Change From Baseline in Myocardial Efficiency (Work Performed/Myocardial Oxygen Consumption [MVO2]) Assessed at Rest at 13 weeks and 1 more. Started Sep 2010; status: completed.
02
Drugs
albiglutide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT01357850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01357850.